Sirolimus-eluting cobalt alloyed stents in treating patients with coronary artery disease: six-month angiographic and one-year clinical follow-up result A prospective, historically controlled, multi-center clinical study
- Author:
- No author available
- Journal Title:
- CHINESE MEDICAL JOURNAL
- Issue:
- 7
- DOI:
- No doi available
- Key Word:
- instrumentation;coronary angiography;sirolimus;stents;treatment outcome
Abstract： Background The emergence of drug-eluting stents (DES) has dramatically reduced the incidence of in-stent restenosis.This study was conducted to evaluate the safetyand efficacy of sirolimus-eluting cobalt-chrome stents (Firebird 2) for treating patients with coronary artery disease.Methods Sixty-seven patients with de novo or non-stented restenostic coronary lesions were chosen to receive the Firebird 2 stent as the final treatment (Firebird 2 group). Another 49 consecutive patients were implanted with bare cobalt alloyed stents (Driver, Medtronic) withit the previous six months and served as historical controls (control group).Baseline clinical characteristics, angiographic features, procedural results, 30-day, 6-month and 12-month clinical follow-up regarding the occurrence of major adverse cardiac events (MACE), as well as the primary endpoint of late lumen loss at 6-month angiographic follow-up were compared between the two groups.Results The demographic characteristics were similar between the two groups despite more patients in the Firebird 2group who underwent previous percutaneous coronary intervention (22.4% vs 8.2%, P=0.0418) and who had diabetes mellitus (29.9% vs 12.2%, P=0.0253). In the Firebird 2 group, the mean diameter of the reference vessel was smaller((2.79±0.46) mm vs (2.98±0.49) mm, P=0.0175) and more stents were implanted for each lesion (1.28±0.52 vs 1.10±0.30, P=0.0060). Other angiographic, procedural results and the device success rate were similar between the two groups. The MACE rate at 30-day and 3-month was the same, but significantly fewer MACE occurred in the Firebird 2group at 6- and 12-month follow-up (1.5% vs 12.2% at 6 month, P=0.0168; 1.5% vs 26.5% at 12 month, P＜0.0001). The primary endpoint of late lumen loss at 6-month angiographic follow-up was significantly reduced in the Firebird 2 group (in-stent: (0.05±0.09) mm vs (0.98±0.61) mm; in-segment: (0.05±0.18) mm vs (0.72±0.59) mm; P＜0.0001) than the control group. One patient in the Firebird 2 group had in-segment restenosis (1.3%) while the rate in the control group (38.1%) was significantly higher, P＜0.0001. Intravascular ultrasound examination was performed in 70.1% of patients in the Firebird 2 group and revealed that the percentage of volumetric obstruction was (1.26± 1.05) %. No stent thrombosis was observed ineither group at 12-month follow-up.Conclusion The Firebird 2 sirolimus-eluting cobalt alloyed stent is safe and feasible in treating patients with coronary artery disease.
- [1]LIU Hai-bo,XU Bo,GAO Run-lin,etc.Outcomes of using Firebird rapamycin eluting stents in routine coronary intervention practice: one-year results from the pilot study of Firebird in China registry[J].2006,(7).
- [2]ZHANG Qi,ZHANG Rui-yan,ZHANG Jian-sheng,etc.One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease[J].2006,(2).
- [3]ZHANG Qi,FANG Yue-hua,ZHANG Rui-yan,etc.Drug-eluting stents improve clinical outcomes in Chinese diabetic patients with de novo coronary artery disease[J].2006,(18).
- [4]XU Bo,LI Jian-jun,YANG Yue-jin,etc.A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients[J].2006,(7).
- [5]LI Chong-jian,GAO Run-lin,YANG Yue-jin,etc.The influence of diabetes mellitus on the procedural and in-hospital outcomes after elective percutaneous coronary intervention[J].2005,(14).
- [6]Jens Hagemeister,Frank M Baer,Robert HG SchwingerHans W Höpp.Compliance of a cobalt chromium coronary stent alloy - the COVIS trial[J].2005,6(1).
- [7]Weissman NJ,Mintz GS.Intravascular ultrasound in the drug-eluting stent era.[J].2006,48(3).
- [8]Iakovou I,Schmidt T,Bonizzoni E,etc.Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.[J].2005,293(17).
- [9]Raja SG,Dreyfus GD.Efficacy and safety of drug-eluting stents: current best available evidence.[J].2006,21(6).
- [10]Brunner La Rocca HP,Zutter A,Zellweger M,etc.Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET).[J].2005,366(9489).
- [11]Serruys PW,Garcia Garcia HM,Rademaker TA,etc.Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial.[J].2006,67(2).
- [12]Muzaffer Degertekin,Patrick Serruys,Kengo Tanabe,etc.Long-Term Follow-Up of Incomplete Stent Apposition in Patients Who Received Sirolimus-Eluting Stent for De Novo Coronary LesionsAn Intravascular Ultrasound Analysis[J].2003,108(22).
- [13]Dean J, Kereiakes,David A, Cox,James B, Hermiller,etc.Usefulness of a cobalt chromium coronary stent alloy.[J].2003,92(4).
- [14]Moses JW,Yock PG,Fitzgerald PJ,etc.Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis.[J].2005,46(6).
- [15]Mark J, Eisenberg,Kristin J, Konnyu.Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis.[J].2006,98(3).
- [16]Antonio Colombo,Janusz Drzewiecki,Adrian Banning,etc.Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions[J].2003,108(7).
- [17]Shaw LK,Kramer JM,Schulman KA,etc.Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.[J].2007,297(2).
- [18]Popma JJ,Leon MB,Caputo RP,etc.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.[J].2003,349(14).
- [19]C, von Birgelen,C, Di Mario,W, Li,etc.Morphometric analysis in three-dimensional intracoronary ultrasound: an in vitro and in vivo study performed with a novel system for the contour detection of lumen and plaque.[J].1996,132(3).